Germany· DE-A57-c9d1bacd1ba055e0
Ambrax
A medicinal product containing sepia officinalis trit. d4, strychnos ignatii trit d3, hyoscyamus niger trit d3, ambra grisea trit. d2, registered in Germany by Homviora Arzneimittel Dr. Hagedorn Gmbh & Co. Kg.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Sepia Officinalis Trit. D4, Strychnos Ignatii Trit D3, Hyoscyamus Niger Trit D3, Ambra Grisea Trit. D2
- Manufacturer
- Homviora Arzneimittel Dr. Hagedorn Gmbh & Co. Kg
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2e0685a6-996e-4419-a866-66e25c55e330 GET /v1/drugs/2e0685a6-996e-4419-a866-66e25c55e330?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Sepia Officinalis Trit. D4, Strychnos Ignatii Trit D3, Hyoscyamus Niger Trit D3, Ambra Grisea Trit. D2",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about sepia officinalis trit. d4, strychnos ignatii trit d3, hyoscyamus niger trit d3, ambra grisea trit. d2.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.